Literature DB >> 17156401

Severity of pulmonary hypertension during vaso-occlusive pain crisis and exercise in patients with sickle cell disease.

Roberto F Machado1, A Kyle Mack, Sabrina Martyr, Christopher Barnett, Peter Macarthur, Vandana Sachdev, Inez Ernst, Lori A Hunter, Wynona A Coles, James P Nichols, Gregory J Kato, Mark T Gladwin.   

Abstract

Pulmonary hypertension is associated with sudden death and is a risk factor for mortality in adult patients with sickle cell disease. The high mortality despite only mild-to-moderate increases in pulmonary vascular resistance remains an unresolved paradox. Accordingly, little is known about the cardiovascular effects of stressors, such as vaso-occlusive pain crisis (VOC) and exercise, which may acutely increase pulmonary pressures and impair right heart function. We therefore evaluated pulmonary artery pressures by echocardiogram in 25 patients with sickle cell disease in steady-state and during VOC, and by right heart catheterisation with exercise in a second cohort of 21 patients to determine whether pulmonary hypertension worsens during acute cardiopulmonary stress. TRV increased during VOC (P < 0.001), and the increased pulmonary pressures during VOC were associated with decreases in haemoglobin levels (P < 0.001), and increases in lactate dehydrogenase (P < 0.001) and plasma haemoglobin levels (P = 0.03). During exercise stress performed during cardiac catheterisation, mean pulmonary artery pressures (P < 0.001) and pulmonary vascular resistance increased (P < 0.001) in all subjects. These data suggest that acute elevations in pulmonary pressures during VOC or exercise may contribute to morbidity and mortality in patients with sickle cell disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17156401      PMCID: PMC2040190          DOI: 10.1111/j.1365-2141.2006.06417.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  41 in total

Review 1.  Pulmonary vascular disease and pregnancy: current controversies, management strategies, and perspectives.

Authors:  B M Weiss; O M Hess
Journal:  Eur Heart J       Date:  2000-01       Impact factor: 29.983

Review 2.  Hemoglobin and the paracrine and endocrine functions of nitric oxide.

Authors:  Alan N Schechter; Mark T Gladwin
Journal:  N Engl J Med       Date:  2003-04-10       Impact factor: 91.245

Review 3.  Nitric oxide's reactions with hemoglobin: a view through the SNO-storm.

Authors:  Mark T Gladwin; Jack R Lancaster; Bruce A Freeman; Alan N Schechter
Journal:  Nat Med       Date:  2003-05       Impact factor: 53.440

4.  Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease.

Authors:  M Aslan; T M Ryan; B Adler; T M Townes; D A Parks; J A Thompson; A Tousson; M T Gladwin; R P Patel; M M Tarpey; I Batinic-Haberle; C R White; B A Freeman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

5.  Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?

Authors:  Claudia R Morris; Sidney M Morris; Ward Hagar; Jane Van Warmerdam; Susan Claster; Diane Kepka-Lenhart; Lorenzo Machado; Frans A Kuypers; Elliott P Vichinsky
Journal:  Am J Respir Crit Care Med       Date:  2003-03-05       Impact factor: 21.405

6.  Cardiac involvement in thalassemia intermedia: a multicenter study.

Authors:  A Aessopos; D Farmakis; M Karagiorga; E Voskaridou; A Loutradi; A Hatziliami; J Joussef; J Rombos; D Loukopoulos
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

7.  Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease.

Authors:  Christopher D Reiter; Xunde Wang; Jose E Tanus-Santos; Neil Hogg; Richard O Cannon; Alan N Schechter; Mark T Gladwin
Journal:  Nat Med       Date:  2002-11-11       Impact factor: 53.440

8.  Divergent nitric oxide bioavailability in men and women with sickle cell disease.

Authors:  Mark T Gladwin; Alan N Schechter; Frederick P Ognibene; Wynona A Coles; Christopher D Reiter; William H Schenke; Gyorgy Csako; Myron A Waclawiw; Julio A Panza; Richard O Cannon
Journal:  Circulation       Date:  2003-01-21       Impact factor: 29.690

Review 9.  An emerging role for nitric oxide in sickle cell disease vascular homeostasis and therapy.

Authors:  Christopher D Reiter; Mark T Gladwin
Journal:  Curr Opin Hematol       Date:  2003-03       Impact factor: 3.284

10.  Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival.

Authors:  Oswaldo Castro; Mohammed Hoque; Bernice D Brown
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113

View more
  37 in total

1.  Control of nectarine fruits postharvest fungal rots caused by Botrytis Cinerea and Rhizopus Stolonifer via some essential oils.

Authors:  Mohammad Tahmasebi; Abdollah Golmohammadi; Ali Nematollahzadeh; Mahdi Davari; Esmaeil Chamani
Journal:  J Food Sci Technol       Date:  2019-12-09       Impact factor: 2.701

2.  Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies.

Authors:  Robyn J Barst; Kamal K Mubarak; Roberto F Machado; Kenneth I Ataga; Raymond L Benza; Oswaldo Castro; Robert Naeije; Namita Sood; Paul S Swerdlow; Mariana Hildesheim; Mark T Gladwin
Journal:  Br J Haematol       Date:  2010-02-17       Impact factor: 6.998

3.  The proverbial chicken or the egg? Dissection of the role of cell-free hemoglobin versus reactive oxygen species in sickle cell pathophysiology.

Authors:  Megan L Krajewski; Lewis L Hsu; Mark T Gladwin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-05-23       Impact factor: 4.733

Review 4.  Cardiovascular abnormalities in sickle cell disease.

Authors:  Mark T Gladwin; Vandana Sachdev
Journal:  J Am Coll Cardiol       Date:  2012-03-27       Impact factor: 24.094

5.  Hemodynamic predictors of mortality in adults with sickle cell disease.

Authors:  Alem Mehari; Shoaib Alam; Xin Tian; Michael J Cuttica; Christopher F Barnett; George Miles; Dihua Xu; Catherine Seamon; Patricia Adams-Graves; Oswaldo L Castro; Caterina P Minniti; Vandana Sachdev; James G Taylor; Gregory J Kato; Roberto F Machado
Journal:  Am J Respir Crit Care Med       Date:  2013-04-15       Impact factor: 21.405

6.  Is resistance futile?: Hemodynamics in sickle cell disease.

Authors:  Kerri Akaya Smith; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2013-04-15       Impact factor: 21.405

Review 7.  Pathophysiology and treatment of pulmonary hypertension in sickle cell disease.

Authors:  Victor R Gordeuk; Oswaldo L Castro; Roberto F Machado
Journal:  Blood       Date:  2016-01-12       Impact factor: 22.113

8.  Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective.

Authors:  Roberto F Machado; Mark T Gladwin
Journal:  Chest       Date:  2010-06       Impact factor: 9.410

9.  An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease.

Authors:  Elizabeth S Klings; Roberto F Machado; Robyn J Barst; Claudia R Morris; Kamal K Mubarak; Victor R Gordeuk; Gregory J Kato; Kenneth I Ataga; J Simon Gibbs; Oswaldo Castro; Erika B Rosenzweig; Namita Sood; Lewis Hsu; Kevin C Wilson; Marilyn J Telen; Laura M Decastro; Lakshmanan Krishnamurti; Martin H Steinberg; David B Badesch; Mark T Gladwin
Journal:  Am J Respir Crit Care Med       Date:  2014-03-15       Impact factor: 21.405

10.  Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease.

Authors:  Nathalie Sabaa; Lucia de Franceschi; Philippe Bonnin; Yves Castier; Giorgio Malpeli; Haythem Debbabi; Ariane Galaup; Micheline Maier-Redelsperger; Sophie Vandermeersch; Aldo Scarpa; Anne Janin; Bernard Levy; Robert Girot; Yves Beuzard; Christophe Leboeuf; Annie Henri; Stéphane Germain; Jean-Claude Dussaule; Pierre-Louis Tharaux
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.